CD274 and hepatocellular carcinoma: Consequently, therapies involving immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), or cytotoxic T-lymphocyte antigen 4 (CTLA-4) have been approved by the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration of China (NMPA) for use in HCC, either as monotherapy or in combination.